---
title: "Dihexa: The Nootropic Peptide 10 Million Times Stronger Than BDNF"
description: "A complete guide to Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide), the angiotensin IV analog studied for cognitive enhancement via the HGF/c-Met pathway."
image: /images/articles/dihexa.webp
date: 2026-02-15
category: "Peptide Guides"
tags: ["dihexa", "nootropic", "cognitive enhancement", "HGF", "c-Met", "synaptogenesis", "neuropeptide"]
author: "PeptideRundown Team"
---

# Dihexa: The Nootropic Peptide 10 Million Times Stronger Than BDNF

A single claim put Dihexa on the map: it's **10 million times more potent** than brain-derived neurotrophic factor at forming new synapses.

That number comes from peer-reviewed research at Washington State University, not Reddit speculation. Whether it translates to real-world cognitive gains is a different question entirely.

> **Key Takeaways**
>
> - **Derived from angiotensin IV**, a fragment of the blood pressure hormone angiotensin II
> - **Works through the HGF/c-Met pathway**, promoting new synapse formation in the brain
> - **10 million times more potent than BDNF** at driving synaptogenesis in vitro
> - **Orally bioavailable**, unlike most peptides that require injection
> - **All data is preclinical** with zero human clinical trials completed
> - **Unregulated** in most countries but not FDA-approved for any use

## What Is Dihexa?

Dihexa (also called **N-hexanoic-Tyr-Ile-(6) aminohexanoic amide**) is a synthetic peptide analog of angiotensin IV. It was developed by **Dr. Joseph Harding** and **Dr. John Wright** at Washington State University.

| Feature | Detail |
|---------|--------|
| **Chemical Name** | N-hexanoic-Tyr-Ile-(6) aminohexanoic amide |
| **Type** | Modified dipeptide (angiotensin IV analog) |
| **Molecular Weight** | ~507 Da |
| **Origin** | Designed at Washington State University |
| **Primary Research** | Preclinical (animal and in vitro only) |
| **FDA Status** | Not approved for any indication |
| **Route** | Oral, subcutaneous, intranasal |

The compound was specifically engineered to be resistant to enzymatic breakdown, giving it a much longer half-life than natural angiotensin IV.

For a deeper compound profile, check out the [Dihexa overview on PeptideArc](https://peptidearc.com).

## How Dihexa Works

Understanding Dihexa requires a detour through an unexpected pathway: the one connecting blood pressure regulation to memory formation.

### The Angiotensin IV Connection

Angiotensin II is best known for raising blood pressure. When enzymes break it down further, a fragment called **angiotensin IV** is produced.

In the 1990s, Harding and Wright discovered that angiotensin IV had a surprising property: it enhanced memory and learning in animal models. But angiotensin IV itself is fragile. It gets chewed up by peptidases within minutes.

- **Angiotensin IV binds AT4 receptors** in the hippocampus and cortex
- **AT4 receptors are now identified as HGF/c-Met receptors** on the cell surface
- **HGF (hepatocyte growth factor)** is a potent driver of synapse formation

([Wright & Harding, 2011](https://pubmed.ncbi.nlm.nih.gov/21530510/))

### The HGF/c-Met Pathway: Building New Synapses

This is where Dihexa's claimed potency comes from.

HGF normally binds to c-Met receptors on neurons, triggering a cascade that results in **new dendritic spine formation**. Dendritic spines are the physical structures where synapses form. More spines typically means more connections between neurons.

Dihexa amplifies this process. Specifically, it acts as an allosteric modulator of HGF, making it bind more effectively to c-Met.

- **Increases HGF/c-Met signaling** without replacing HGF itself
- **Promotes dendritic spine growth** in the hippocampus
- **Drives synaptogenesis** at concentrations far below what BDNF requires
- **Crosses the blood-brain barrier** when given orally

> **Key Finding:** In cell culture, Dihexa drove new synapse formation at picomolar concentrations, roughly **10 million times lower** than the concentration of BDNF needed for the same effect. ([McCoy et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23303057/))

### Why Synaptogenesis Matters for Cognition

Synaptic density correlates with cognitive function across species. Neurodegenerative diseases like Alzheimer's are fundamentally diseases of **synapse loss**.

The theory behind Dihexa is straightforward: if you can rebuild lost synapses or create new ones, you can restore or enhance cognitive function. That's a big "if" in practice, but the biological logic is sound.

## Research and Preclinical Data

### The Harding and Wright Studies

Nearly everything we know about Dihexa traces back to the lab at Washington State University.

**The landmark 2013 paper** in the *Journal of Pharmacology and Experimental Therapeutics* established the core claims.

| Parameter | Detail |
|-----------|--------|
| **Model** | Scopolamine-impaired rats |
| **Route** | Oral administration |
| **Test** | Morris water maze (spatial learning) |
| **Design** | Multiple dose groups vs. control |

**Results:**

| Condition | Performance |
|-----------|------------|
| **Normal rats** | Baseline learning speed |
| **Scopolamine-impaired (no treatment)** | Severely impaired spatial memory |
| **Scopolamine-impaired + Dihexa (oral)** | **Restored to near-normal performance** |
| **Scopolamine-impaired + Dihexa (subcutaneous)** | Restored to near-normal performance |

The fact that oral dosing worked is significant. Most peptides are destroyed in the gut before reaching the bloodstream.

([McCoy et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23303057/))

### Aged Rat Cognition Studies

A separate experiment looked at naturally aged rats, not chemically impaired ones.

Old rats given Dihexa performed significantly better on spatial memory tasks than untreated aged controls. Their performance approached that of young adult rats.

- **Aged rats (24+ months)** showed marked cognitive decline on baseline testing
- **After Dihexa treatment**, spatial navigation improved substantially
- **Hippocampal spine density increased**, suggesting real structural changes in the brain

([Benoist et al., 2011](https://pubmed.ncbi.nlm.nih.gov/22044908/))

> **Key Finding:** Dihexa didn't just prevent decline in a disease model. It reversed age-related cognitive impairment in otherwise healthy old rats.

### Synaptogenesis Confirmation

Using organotypic hippocampal slice cultures, the Wright lab demonstrated that Dihexa directly increased the number of functional synapses.

| Measurement | Dihexa vs. Control |
|-------------|-------------------|
| **Dendritic spine density** | Significantly increased |
| **Spine morphology** | More mushroom-shaped (mature) spines |
| **HGF/c-Met activation** | Confirmed via phosphorylation assays |
| **Effect blocked by c-Met inhibitor** | Yes, confirming mechanism |

This last point is important. When researchers blocked c-Met with a specific inhibitor, Dihexa's effects disappeared. That confirms HGF/c-Met is the actual pathway, not some off-target effect.

([McCoy et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23303057/))

## Oral Bioavailability

This is one of Dihexa's most interesting properties.

Most peptides have terrible oral bioavailability. Stomach acid and digestive enzymes break them apart before they can reach the bloodstream. That's why peptides like BPC-157 and most growth hormone secretagogues are typically injected.

Dihexa was specifically designed to resist enzymatic degradation. The **N-hexanoic acid modification** and the **aminohexanoic amide C-terminus** protect the core structure from peptidases.

| Route | Effectiveness in Animal Studies |
|-------|-------------------------------|
| **Oral** | Active at low doses; crossed BBB |
| **Subcutaneous** | Active; comparable to oral in some models |
| **Intranasal** | Reported anecdotally; limited formal data |
| **Intravenous** | Used in some early experiments |

> **Bottom line:** Dihexa is one of the rare peptides where oral dosing appears to work. That said, all bioavailability data comes from rodent studies. Human pharmacokinetics remain unknown.

## Dosing

> **Important:** No human clinical trials exist for Dihexa. All dosing information comes from animal research and anecdotal user reports. This is not medical advice.

| Parameter | Reported Range |
|-----------|---------------|
| **Sublingual/Oral dose** | 5-30 mg/day |
| **Subcutaneous dose** | 1-10 mg/day |
| **Intranasal** | Variable; no standardized protocol |
| **Cycle length** | Typically 2-4 weeks on, 2-4 weeks off |
| **Timing** | Morning, often on an empty stomach |

### What Users Report

Anecdotal reports from nootropic communities describe:

- **Improved verbal fluency** within days of starting
- **Better recall and working memory** during the cycle
- **Enhanced dream vividness** as a common early sign
- **Tolerance development** after 2-3 weeks of continuous use

These are self-reports with all the usual caveats: no controls, placebo effects, selection bias, and variable compound quality.

## Safety Concerns

This is where caution becomes critical. Dihexa has **zero human safety data**.

### Known Risks and Theoretical Concerns

| Concern | Explanation |
|---------|-------------|
| **No human trials** | We don't know the therapeutic window, toxicity profile, or drug interactions |
| **HGF/c-Met and cancer** | The HGF/c-Met pathway is overactive in many cancers; upregulating it raises theoretical oncology concerns |
| **Blood pressure effects** | As an angiotensin derivative, interactions with cardiovascular function are plausible |
| **Unknown long-term effects** | Chronic synaptogenesis modulation could have unpredictable neurological consequences |
| **Compound purity** | No pharmaceutical-grade Dihexa exists; research chemical quality varies wildly |

### The Cancer Question

This deserves its own section because it's the most serious concern.

HGF/c-Met signaling is a known driver of tumor growth, metastasis, and angiogenesis in multiple cancer types. Pharmaceutical companies have spent billions developing c-Met **inhibitors** as cancer drugs.

Dihexa does the opposite. It **enhances** HGF/c-Met signaling.

- **c-Met overexpression** is found in lung, breast, colon, kidney, and liver cancers
- **HGF promotes tumor cell migration** and invasion in vitro
- **No studies have evaluated** whether Dihexa promotes or accelerates tumor growth

> **Important:** This doesn't mean Dihexa causes cancer. It means the pathway it activates is one that cancer researchers are actively trying to suppress. The risk is theoretical but not trivial, and no one has studied it.

([Birchmeier et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12778124/))

### Who Should Avoid Dihexa

Based on the mechanism of action, the following groups should exercise extreme caution:

- **Anyone with a personal or family history of cancer** due to HGF/c-Met concerns
- **People on blood pressure medications** due to angiotensin pathway interactions
- **Pregnant or nursing women** with zero safety data available
- **Anyone under 25** whose brain is still developing

## Dihexa vs. Other Nootropic Peptides

Several other peptides are used for cognitive enhancement. Here's how they compare.

| Feature | Dihexa | Selank | Semax |
|---------|--------|--------|-------|
| **Type** | Angiotensin IV analog | Tuftsin analog | ACTH(4-10) analog |
| **Primary mechanism** | HGF/c-Met synaptogenesis | GABA modulation, BDNF | BDNF, NGF upregulation |
| **Main effects** | Memory, synapse formation | Anxiety reduction, focus | Focus, neuroprotection |
| **Oral bioavailability** | Yes | Poor (intranasal preferred) | Poor (intranasal preferred) |
| **Human clinical data** | None | Limited (Russia) | Limited (Russia) |
| **FDA approved** | No | No | No |
| **Primary research country** | United States | Russia | Russia |
| **Cancer pathway concern** | Yes (HGF/c-Met) | No | No |
| **Typical route** | Oral/sublingual | Intranasal | Intranasal |

### Selank

Selank is a synthetic analog of the immune peptide tuftsin. Developed at the Russian Academy of Sciences, it's approved in Russia as an anxiolytic.

- **Modulates GABA-A receptors**, producing calming effects without sedation
- **Increases BDNF expression** in the hippocampus
- **Better studied in humans** than Dihexa, though still limited by Western standards
- **Lower risk profile** with no known oncology concerns

For people seeking anxiety relief alongside mild cognitive benefits, Selank is the more conservative choice.

### Semax

Semax is a synthetic fragment of ACTH (adrenocorticotropic hormone). Also developed in Russia and approved there for stroke recovery and cognitive enhancement.

- **Upregulates BDNF and NGF** (nerve growth factor) in the brain
- **Neuroprotective properties** demonstrated in stroke models
- **Stimulating rather than calming**, unlike Selank
- **More human data available** than Dihexa, particularly from Russian clinical practice

> **Bottom line:** Dihexa is the most potent synaptogenic compound of the three, but also carries the most uncertainty. Selank and Semax have longer track records and lower theoretical risk, even if the evidence base isn't up to Western clinical trial standards.

## Potential Applications Under Investigation

Researchers have proposed Dihexa as a candidate for several conditions, though none have progressed to human trials.

| Condition | Rationale |
|-----------|-----------|
| **Alzheimer's disease** | Synapse loss is the core pathology; Dihexa rebuilds synapses |
| **Age-related cognitive decline** | Demonstrated reversal in aged rat models |
| **Traumatic brain injury** | HGF promotes neural repair and regeneration |
| **Parkinson's disease** | c-Met signaling supports dopaminergic neuron survival |
| **Stroke recovery** | HGF is neuroprotective in ischemia models |

The Alzheimer's application is the most discussed. Current Alzheimer's drugs target amyloid plaques or acetylcholinase. Dihexa takes a fundamentally different approach: instead of removing what's damaging synapses, it builds new ones.

Whether that strategy works in the complex environment of an Alzheimer's brain, where ongoing neuroinflammation and protein aggregation continue, remains unknown.

## Legal Status and Availability

Dihexa exists in a regulatory gray area in most countries.

| Region | Status |
|--------|--------|
| **United States** | Not scheduled; sold as a "research chemical" |
| **European Union** | Varies by country; generally unregulated |
| **Australia** | Not listed on TGA schedules; legal status ambiguous |
| **Russia** | Not approved (unlike Selank and Semax) |
| **Canada** | Not approved; available through research chemical suppliers |

In the U.S., Dihexa is not a controlled substance and not FDA-approved. It can be purchased from research chemical vendors who label it "not for human consumption." The quality, purity, and actual content of these products varies significantly.

> **Important:** Buying Dihexa as a research chemical and self-administering it means you are your own guinea pig. There are no guaranteed purity standards, no dosing guidelines validated in humans, and no safety monitoring.

Check our [peptide legality guide](/articles/are-peptides-legal-fda-regulations-2026) for full details.

## Frequently Asked Questions

### What does Dihexa do?

Dihexa activates the HGF/c-Met signaling pathway in the brain, which drives the formation of new synapses between neurons. In animal studies, this translated to improved spatial memory, faster learning, and reversal of age-related cognitive decline.

In the nootropic community, users report improvements in verbal fluency, working memory, and mental clarity. But these are anecdotal reports without controlled conditions.

### How long does Dihexa take to work?

Anecdotal reports suggest noticeable effects within **3-7 days**, with peak benefits around **2-3 weeks** of use. Some users describe vivid dreams as the earliest sign.

Structural changes like new synapse formation would take longer to develop fully. In animal studies, cognitive improvements were measured after **1-2 weeks** of dosing.

### Is Dihexa safe?

Unknown. There are no human safety studies. The animal data doesn't show obvious acute toxicity, but the theoretical concern about HGF/c-Met and cancer risk is real and unstudied.

Anyone using Dihexa is accepting unknown risks. That's a personal decision, but it should be made with full awareness of what "no human data" actually means.

### Can Dihexa cause cancer?

There is no evidence that Dihexa causes cancer. But there is also no evidence that it doesn't.

The HGF/c-Met pathway it activates is a well-documented oncogenic pathway. Major pharmaceutical companies are developing c-Met inhibitors specifically to fight cancer. Activating this same pathway for cognitive benefit creates a theoretical tension that hasn't been resolved by research.

### Can I stack Dihexa with other nootropics?

Some users combine Dihexa with racetams, Selank, or other cognitive enhancers. No interaction studies exist. If you choose to stack, starting with one compound at a time and adding others gradually is the most cautious approach.

### Is Dihexa better than Semax or Selank?

"Better" depends on what you're after.

- **For raw synaptogenic potency**, Dihexa is in a class of its own
- **For anxiolytic effects with mild cognition boost**, Selank is more appropriate
- **For stimulating focus and neuroprotection**, Semax has more supporting data
- **For risk tolerance**, Selank and Semax are considerably safer bets

### Why hasn't Dihexa gone to human trials?

Several possible reasons. The HGF/c-Met cancer concern makes FDA approval of human trials more complex. Funding for nootropic peptides is limited compared to obesity or cancer drugs. And the original researchers at WSU may lack the commercial partnerships needed to fund expensive clinical programs.

It's also worth noting that "10 million times more potent" is an in vitro comparison. Regulators care about in vivo efficacy and safety in humans, which requires years of additional work.

## The Bottom Line

Dihexa is one of the most fascinating peptides in nootropic research. The science behind it is real: HGF/c-Met-driven synaptogenesis is a legitimate biological mechanism, and the potency data from the Wright/Harding lab is striking.

But fascinating science doesn't equal a safe or effective drug. Every piece of Dihexa data comes from rats or cell cultures. No one knows the right dose for humans, the long-term risks, or whether the cognitive benefits seen in rodents translate to people.

The HGF/c-Met cancer concern isn't something to brush off. It may turn out to be a non-issue at the doses used for cognition. Or it may not. Without human data, we're guessing.

If you're considering Dihexa, understand what you're signing up for: a genuinely promising compound with genuinely unknown risks. For most people seeking cognitive enhancement, peptides with more safety data like Selank or Semax are the more reasonable starting point.

**Related reading:**
- [What Are Peptides? Beginner's Guide](/articles/what-are-peptides-beginners-guide)
- [Peptide Side Effects: What to Know](/articles/peptide-side-effects-what-to-know)
- [Are Peptides Legal? FDA Regulations 2026](/articles/are-peptides-legal-fda-regulations-2026)

For compound profiles and sourcing info, visit [PeptideArc](https://peptidearc.com).
